Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals (REGN) is a US-based biotechnology company known for developing monoclonal antibody therapies and using human genetics to inform drug discovery. Its leading marketed products include EYLEA for retinal disease and Dupixent (co‑developed with Sanofi) for certain inflammatory conditions — both are material revenue drivers. The firm combines laboratory platforms (VelocImmune) and the Regeneron Genetics Center to identify and advance targets across ophthalmology, immunology, oncology and rare diseases. Investors should note Regeneron’s strengths in proprietary discovery technology and a deep pipeline, balanced by typical sector risks: R&D intensity, regulatory approval uncertainty, patent and pricing pressures, and possible revenue concentration around key drugs. With a market capitalisation near $61.4bn, the stock can be volatile around trial, approval and commercial updates. This summary is educational and not financial advice; consider your risk tolerance and consult a financial adviser to determine suitability.
Why It's Moving
Regeneron Eyes Pivotal 2026 With Four Expected FDA Approvals and DUPIXENT Momentum Building Investor Confidence
- FDA Priority Review acceptance for garetosmab (FOP treatment) with August 2026 decision date signals validation of Regeneron's rare disease pipeline strategy, with management guiding for at least four total FDA approvals in 2026.
- DUPIXENT delivered a $17.8 billion full-year 2025 base, while EYLEA HD showed 66% quarter-over-quarter growth in Q4, demonstrating core portfolio momentum offsetting mature product pressure and justifying Street revenue projections of $15.63 billion in 2026.
- Analyst consensus reflects cautious optimism, with 17 Buy ratings and 2 Outperform ratings targeting $868 upside, though the modest 11% gap suggests much of the pipeline upside is already priced in, balanced against R&D spending compression of EBITDA margins from 61.2% in 2021 to projected 35.3% in 2026.
Regeneron Eyes Pivotal 2026 With Four Expected FDA Approvals and DUPIXENT Momentum Building Investor Confidence
- FDA Priority Review acceptance for garetosmab (FOP treatment) with August 2026 decision date signals validation of Regeneron's rare disease pipeline strategy, with management guiding for at least four total FDA approvals in 2026.
- DUPIXENT delivered a $17.8 billion full-year 2025 base, while EYLEA HD showed 66% quarter-over-quarter growth in Q4, demonstrating core portfolio momentum offsetting mature product pressure and justifying Street revenue projections of $15.63 billion in 2026.
- Analyst consensus reflects cautious optimism, with 17 Buy ratings and 2 Outperform ratings targeting $868 upside, though the modest 11% gap suggests much of the pipeline upside is already priced in, balanced against R&D spending compression of EBITDA margins from 61.2% in 2021 to projected 35.3% in 2026.
When is the next earnings date for Regeneron Pharmaceuticals, Inc. (REGN)?
Regeneron Pharmaceuticals' next earnings announcement is estimated to occur between April 28 and May 5, 2026, with most sources projecting dates in late April or early May. The company has not officially confirmed the specific date, but based on historical patterns, the release is expected around April 29-30, 2026. This earnings report will cover the company's first quarter 2026 results. The typical release time is before market open, followed by a conference call at 8:30 AM ET.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Regeneron's stock with a target price of $813.04, indicating growth potential.
Financial Health
Regeneron is producing strong revenue and profits, supported by high cash flow and a robust gross margin.
Dividend
Regeneron Pharmaceuticals offers a low dividend yield of 0.47%, indicating limited returns from dividends. If you invested $1000, you would be paid $4.70 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring REGN
Obesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: September 10, 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: August 3, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Strong product drivers
EYLEA and Dupixent are significant revenue sources and shape near-term cashflow, though sales can be sensitive to competition and reimbursement changes.
Genetics-driven R&D
Regeneron’s genetics and VelocImmune platforms can accelerate target discovery and bespoke antibodies, offering scientific optionality while R&D outcomes remain uncertain.
Regulatory sensitivity
Product approvals, label changes and pricing decisions across markets materially affect valuation; investors should expect updates to move the share price.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
